On December 17, 2024, Stephen Carey, Senior Vice President & Chief Financial Officer of ANI Pharmaceuticals Inc (ANIP, Financial), sold 7,500 shares of the company, according to a SEC Filing. Following this transaction, the insider now owns 154,468 shares of the company.
ANI Pharmaceuticals Inc (ANIP) is a specialty pharmaceutical company that develops, manufactures, and markets branded and generic prescription pharmaceuticals. The company focuses on niche and high-barrier-to-entry opportunities, including controlled substances, oncology products, hormones, and steroids.
Over the past year, Stephen Carey has sold a total of 20,287 shares and has not purchased any shares. The insider transaction history for ANI Pharmaceuticals Inc shows that there have been 0 insider buys and 44 insider sells over the same timeframe.
As of the date of the recent transaction, shares of ANI Pharmaceuticals Inc were trading at $55.79, giving the stock a market cap of $1.132 billion. The stock has a GF Value of $67.24, resulting in a price-to-GF-Value ratio of 0.83, indicating that the stock is modestly undervalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow that the stock has traded at. It also includes a GuruFocus adjustment factor based on the company’s past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
